preferred shares *could* be used to fix a redemption price that is unaffected by the market. More likely SNY insisted they have a way to thwart hostile takeover.
good? new rx was flat. I'd call it "not bad" . I think short side has simply reached exhaustion. They have to let it up once in a while to get delta.
old resistance = new support at 33-34. Just made a new 52 week high so a pullback to support should not be a surprise. On the other hand a retest of resistance at 37 should also be anticipated.
Insulin inhalation [Afrezza]; Sanofi-Aventis
Pharmacology: Dry-powder formulation of insulin, ultra rapid-acting, first-in-class. Used at the start of a meal.
Indication: Type 1 and 2 diabetes mellitus in adults.
Current status: PIII in EU. Launched in US February 2015 – see prescribing data.
UK availability: Uncertain.
Population: Estimated UK prevalence of diagnosed diabetes mellitus was 3.3 million people in 2014; a further
590,000 may be undiagnosed. 90% of people with diabetes have type 2 diabetes. Prevalence of insulin
use in patients with type 2 diabetes increased from 0.7 to 4.3 per 1,000 people between 1991 and 2010.
Sector: Secondary care initiated.
Implications: Needle-free insulin will be attractive to patients, especially those with needle phobia or problems injecting.
Exubera (an inhaled insulin formulation launched in 2006 but discontinued due to poor sales) was not
approved for use by NICE on cost-effectiveness grounds.
Financial: Cost of Afrezza in US is $7.54/day (based on 12units/day). In 2006, Exubera cost £1,100 annually.
Tariff: HRG included.
Efficacy: A PIII study in 518 patients with type 1 diabetes using basal insulin showed that Afrezza was non-inferior
to insulin aspart. Mean HbA1c was reduced by 0.2% with Afrezza vs. 0.4% with insulin aspart. Fasting
blood glucose and bodyweight were also reduced vs. insulin aspart (p=0.003 and p=0.01, respectively). In
a PIII study involving 353 insulin-naïve patients with type 2 diabetes, Afrezza in combination with oral antidiabetic
medicines, decreased mean HbA1c by 0.8% vs. 0.4% with oral medicines alone (p
I take metformin and had GI upset the first week. I expect I can go off of it when I lose some more weight and stick to a diet low in fast carbs.
I think they made mistakes. It was a different drug and the climate was different. ACA has dramatically changed the medical industry. Exhubera probably would have been successful if they gave it some time and improved the delivery device. Some companies are myopic.
OK so in 6 months it will be a year. I expect new scripts to get to a thousand by then. But it will take another year to get to 10K per month the way I see it. I just don't think that script count is a good measure of whether the drug will be accepted in practice at this point in time. Managing diabetes isn't anything like prescribing lipitor after somebody has a stent placed.
Sales won't ramp up until the comfort level with using it rises sufficiently for doctors to prescribe it as the first supplemental insulin instead of a long-acting injection. This will take years, not months. Doctors are risk averse and egotistical. They will stick with what they know rather than get in trouble trying something new. And pushy salesmen just make them more skeptical. What will change their attitudes is case reports in their journals and med school textbooks along with reports from their colleagues. But once they see good results for themselves they will become enthusiastic. The best place to target detailing is in medical school institutions where new doctors will be trained on how to introduce insulin therapy.
good question. straight answer is it can't, directly. It can only supplement the pancreas when it has become exhausted from overwork. There is suggestion and hope that resting the pancreas may improve or prolong its ability to produce insulin. And by lowering the average insulin concentration by supplying a fast acting form it *may* improve insulin sensitivity. With insulin, you become tolerant with larger amounts being needed over time to produce the same therapeutic effect.
The current practice is to give long acting insulin when the pancreas poops out to the extent that metformin no longer controls blood sugar. This is not optimal, since it further reduces insulin sensitivity by providing more insulin than is needed (hence causing hypos) during most of the day, and not enough at mealtime. This practice is due to the convenience of taking a shot once a day and then drinking orange juice to correct the ensuing highs.Afrezza has the potential to alter the standard of care, by inhaling it at mealtime instead of injecting slow insulin every 24 hours. We won't see it being used that way until doctors are convinced in practice that it is a safe and effective alternative to long acting insulin after metformin no longer controls blood sugar adequately. The first target is to replace fast acting injectables in patients who require basal and prandial insulin (end stage disease and T1)
The mechanism of metformin is poorly understood. But it does not stimulate the pancreas to secrete insulin. It acts primarily on the liver to inhibit gluconeogenesis.
So the 200 million registration filed 2/26/15 was for what? Would a long holder be selling at 33? Seems like shorting or the company is selling to me. It seems out of character for the stock to sell off on this news.